Comparative Pharmacology
Head-to-head clinical analysis: BRANCHAMIN 4 versus L GLUTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRANCHAMIN 4 versus L GLUTAMINE.
BRANCHAMIN 4% vs L-GLUTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential branched-chain amino acids (leucine, isoleucine, valine) to correct deficiencies and support protein synthesis in catabolic states; serves as a substrate for energy production and muscle metabolism.
L-glutamine is a conditionally essential amino acid that serves as a precursor for nucleotide synthesis, glutathione production, and energy metabolism. It modulates heat shock protein expression, supports intestinal epithelial cell proliferation, and attenuates glutamine metabolism in cancer cells, particularly in hematologic malignancies.
1-1.5 g/kg/day intravenously, infused at a rate not exceeding 10 g/hour.
Oral: 10-15 g three times daily (30-45 g/day). Powder dissolved in beverage. For sickle cell disease: 0.3 g/kg twice daily (max 30 g/day).
None Documented
None Documented
Clinical Note
moderateL-Glutamine + Lactulose
"The therapeutic efficacy of Lactulose can be decreased when used in combination with L-Glutamine."
Terminal elimination half-life of individual amino acids ranges from 0.5 to 2 hours; clinical context: rapid clearance requires continuous infusion to maintain plasma levels
Terminal half-life approximately 1.5-2 hours in adults; clinically, enteral supplementation requires frequent dosing to maintain plasma levels.
Primarily renal; >90% of infused amino acids are excreted in urine as metabolites (urea, ammonia) within 24 hours; minimal biliary/fecal elimination (<5%)
Renal: ~5-10% unchanged; biliary/fecal: negligible; majority metabolized by enterocytes and liver to glutamate, ammonia, and other amino acids.
Category C
Category C
Amino Acid Supplement
Amino Acid Supplement